First Trading Day of Q4, the New "CNBC Investing Club" With Jim Cramer, the Merck-Ridgeback Biotherapeutics COVID-19 Pill: An Interview With Ridgeback's Co-Founders. Plus, Zoom and Five9 Scrap Their $15B Deal. | Squawk on the Street | Podwise